XENON PHARMACEUTICALS INC.
XENELoading price...
Overview
Previous Close41.94
Open60.56
Ask74.64
Bid44.62
Day's Range58.00 - 62.91
52 Week Range26.74 - 62.91
PE Ratio(TTM)--
Market Cap4.77B
Volume10.63M
Avg. Volume916.83k
12 Months Earnings-306.33M
12 Months Revenue7.50M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Operating Revenue | 7.50M | 7.50M | 0.00 | 0.00 | 9.43M | 18.44M |
| Cost of Revenue | 0.00 | |||||
| Gross Profit | 3.50M | |||||
| Operating Expenses | 348.28M | 325.62M | 279.30M | 214.05M | 138.58M | 97.43M |
| Profit after Tax (Net Income) | -306.33M | -278.23M | -234.33M | -182.39M | -125.37M | -78.88M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Burnaby, Canada
Website: https://www.xenon-pharma.com
President, CEO, Principal Accounting Officer & Director: Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Employees: 358
About Company:
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.